

PTO/SB/08a (01-09)

Approved for use through 02/28/2009. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to collect information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/811,839
		Filing Date	March 30, 2004
		First Named Inventor	Theoharis C. THEOHARIDES
		Art Unit	1615
		Examiner Name	C. S. Hagopian
Sheet	1	of	6
		Attorney Docket Number	2003133.00125US11

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-20070141187	06-21-2007	Theoharides	
	AB*	US-20050220909	10-06-2005	Theoharides	
	AC*	US-6,136,795	10-24-2000	Florio	
	AD*	US-5,876,744	03-02-1999	Della Valle et al.	
	AE*	US-6,162,787	12-19-2000	Sorgente et al.	
	AF*	US-5,972,999	10-26-1999	Murad	
	AG*	US-20010000340	04-19-2001	Chen et al.	
	AH*	US-20020146393	10-10-2002	Bell et al.	
	AI*	US-20060210551	09-21-2006	Lindberg et al.	
	AJ*	US-5,223,257	06-29-1993	Arora	
	AK*	US-5,250,529	10-05-1993	Theoharides	
	AL*	US-5,260,335	11-09-1993	Wagner et al.	
	AM*	US-5,648,355	07-15-1997	Theoharides	
	AN*	US-5,795,905	08-18-1998	McCarthy et al.	
	AO*	US-5,804,594	09-08-1998	Murad	
	AP*	US-5,855,884	01-05-1999	Theoharides	
	AQ*	US-5,980,865	11-09-1999	Ahmed	
	AR*	US-5,994,357	11-30-1999	Theoharides	
	AS*	US-6,020,305	02-01-2000	Theoharides	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
	BA	WO-199833494	08-06-1998	Kosbab	
	BB	WO-200078320	12-28-2000	Joint Juice Inc.	
	BC	GB-2105193	09-12-1984	Glaxo Group Ltd.	
	BD	EP-0426479	05-08-1991	McNeil-PPC, Inc.	

Examiner Signature	/Casey Hagopian/	Date Considered	01/28/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with a single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. * Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number	10/811,839
Filing Date	March 30, 2004
First Named Inventor	Theoharis C. THEOHARIDES
Art Unit	1615
Examiner Name	C. S. Hagopian
Attorney Docket Number	2003133.00125US11

Sheet	2	of	6
-------	---	----	---

[illegible][illegible]

Date Considered	01/28/2010
-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98a(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter office that issued the document, by the letter-code code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the Emperor must be entered in the place of the number of the year. English language symbols as indicated in the document under the WIPO Standard ST.16, if possible. * Applicant is to place a check mark here if "English Language Translation is attached."

PTO/SB/08b (01-09)
Approved for use through 02/28/2009. OMB 0351-0331
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/811,839
		Filing Date	March 30, 2004
		First Named Inventor	Theoharis C. THEOHARIDES
		Art Unit	1615
		Examiner Name	C. S. Hagopian
		Attorney Docket Number	2003133.00125US11
Sheet	3	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CA		International Search Report and Written Opinion, International Patent Application No. PCT/US08/86059, mailed 26 January 2009 (2 pages)	
CB		Russell, A.L. and McCarty, M.F. "Glucosamine for migraine prophylaxis?" Medical Hypotheses, 55(3): 195-198 (2000)	
CC		Matsuda, K. et al., "Inhibitory Effects of Sialic-Acid- or N-Acetylglucosamine-Specific Lectins on Histamine Release Induced by Compound 48/80, Bradykinin and a Polyethylenimine in Rat Peritoneal Mast Cells," Jpn. J. Pharmacol., 64: 1-8 (1994)	
CD		Trichopoulou, A. et al., "Cancer and Mediterranean Dietary Traditions," Cancer Epidemiology, Biomarkers, & Prevention, Vol. 9: 869-873 (Sept. 2000)	
CE		Theoharides, T.C., "The Mast Cell: A Neuroimmunomodulatory Master Player," Int. J. Tiss. Reac. XVIII(1), 1-21 (1996)	
CF		Theoharides, T.C., "Histamine2 (H2)-Receptor Antagonists in the Treatment of Urticaria," Drugs 37: 345-355 (1989)	
CG		Theoharides, T. "Mast Cells and Migraines," Brief Proposal, (1983)	
CH		Morrow, J. et al., "Identification of Skin as a Major Site of Prostaglandin D2 Release Following Oral Administration of Niacin in Human," J. Invest. Derm., Vol. 98(5): 812-815 (1992)	
CI		Weston, A. et al., "Terminal Ileal Mucosal Mast Cells in Irritable Bowel Syndrome," Dig. Diseases and Sci., Vol. 38(9): 1590-1595 (Sept. 1993)	
CJ		Shapiro, G. et al., "Cromolyn Sodium: A Review," Pharmacotherapy, Vol. 5(3): 156-170 (May/June 1985)	
CK		Database WPI: 2001-358435 - XP002221703, "Compositions comprising hyaluronic acid and flavonoids," (2 pages)	
CL		International Search Report issued for PCT/US02/00476, dated December 16, 2002 (6 pages)	
CM		Parodi et al., Arch. Psicol. Neurol. Psichiatr. Vol. 49(3): 299-303 (1988)	
CN		Split et al., "Ketotifen in the Treatment of Chronic Cluster Headache," Headache, Vol. 24(3): 147-148: 1984)	
CO		Unlisted Drugs, Vol. 20(11): 167 (November 1968)	
CP		Debeuckelaere, et al., "Systemic Mast Cell Disease: A review of the literature with special focus on the gastrointestinal manifestations", Acta clinica Belgica, 46, 226-232 (1991)	
CQ		Koblentz, C.S. "Neurotic excoriations and dermatitis artefacta," Dermatologic Clinics, Vol. 14(3): 447-455 (July 1996)	

Examiner Signature	/Casey Hagopian/	Date Considered	01/28/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (01-09)
Approved for use through 02/28/2010, OMB 0351-0311

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 10px 0;"><i>(Use as many sheets as necessary)</i></p>		Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/811,839</td> </tr> <tr> <td>Filing Date</td> <td>March 30, 2004</td> </tr> <tr> <td>First Named Inventor</td> <td>Theoharis C. THEOHARIDES</td> </tr> <tr> <td>Art Unit</td> <td>1615</td> </tr> <tr> <td>Examiner Name</td> <td>C. S. Hagopian</td> </tr> <tr> <td>Attorney Docket Number</td> <td>2003133.00125US11</td> </tr> </table>		Application Number	10/811,839	Filing Date	March 30, 2004	First Named Inventor	Theoharis C. THEOHARIDES	Art Unit	1615	Examiner Name	C. S. Hagopian	Attorney Docket Number	2003133.00125US11
Application Number	10/811,839														
Filing Date	March 30, 2004														
First Named Inventor	Theoharis C. THEOHARIDES														
Art Unit	1615														
Examiner Name	C. S. Hagopian														
Attorney Docket Number	2003133.00125US11														
Sheet	4	of	6												

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CR	Tauberg, J. et al., "Stress-induced urticaria associated with local anesthetic administration," <i>Anesthesia Progress</i> , Vol. 30(6): 199-200 (1983)	
	CS	Theoharides, T.C. "Mast Cells: The Immune Gate To The Brain," <i>Life Sciences</i> , Vol. 46: 607-617 (1990)	
	CT	Lambrachi-Hall, M. et al., "Serotonin Release From Rat Brain Mast Cells In Vitro," <i>Neuroscience</i> , Vol. 39(1) 199-207 (1990)	
	CU	Dimitriadou, V. et al., "HISTOCHEMICAL AND ULTRASTRUCTURAL CHARACTERISTICS OF RAT BRAIN PERIVASCULAR MAST CELLS STIMULATED WITH COMPOUND 48/80 AND CARBACHOL," <i>Neuroscience</i> , Vol. 39(1): 209-224 (1990)	
	CV	Pearce, F.L. "Mast cell heterogeneity," <i>TIPS</i> : 165-167 (April 1983)	
	CW	Theoharides, T.C. and Douglas, W.W. "SOMATOSTATIN INDUCES HISTAMINE SECRETION FROM RAT PERITONEAL MAST CELLS," <i>Endocrinology</i> , Vol. 102(5): 1637-1640 (Nov. 7, 1977)	
	CX	Sundaram, K. et al., "Antagonists of luteinizing hormone releasing hormone bind to rat mast cells and induce histamine release," <i>Agents and Actions</i> , Vol. 25(3/4): 307-313 (1988)	
	CY	Prior, A. and Read, N.W. "Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5HT ₃ receptor antagonist, in patients with irritable bowel syndrome (IBS)," <i>Brit. Soc. of Gastroenterol.</i> , A1174	
	CZ	Mathias, J. et al., "Debilating 'Functional' Bowel Disease Controlled by Leuprolide Acetate, Gonadotropin-Releasing Hormone (GnRH) Analog," <i>Digestive Diseases and Sciences</i> , Vol. 34(5): 761-766 (May 1989)	
	CA1	Read, N.W. "Irritable bowel syndrome (IBS)—definition and pathophysiology," <i>Vol. 130: 7-13 (1987)</i>	
	CB1	Stefanini, G.F. et al., "Oral disodium cromoglycate treatment on irritable bowel syndrome: An open study on 101 subjects with diarrheic type," <i>Vol. 87: 55-57 (1992)</i>	
	CC1	International Search Report issued for PCT/US95/01392, dated May 31, 1995 (4 pages)	
	CD1	Hendriks, J. et al., "Flavonoids Influence Monocytic CTPase Activity and Are Protective In Experimental Allergic Encephalitis," <i>J. Exp. Med.</i> , Vol. 200(12): 1667-1672 (2004)	
	CE1	Mezzapesa, D. et al., "Glatiramer acetate in multiple sclerosis," <i>Expert Rev. Neurotherapeutics</i> (5): 451-458 (2005)	
	CF1	Gupta, E. et al., "Lovastatin and Extended-Release Niacin Combination Product: The First Drug Combination for the Management of Hyperlipidemia," <i>Heart Disease</i> , Vol. 4, 124-137 (2002)	
	CG1	Owens, M.J. and Nemeroff, C.B., "Physiology and Pharmacology of Corticotropin-releasing Factor," <i>Pharmacological Reviews</i> , Vol. 43(4): 425-615 (1991)	
	CH1	Devlin, Thomas (ed): <i>Textbook of Biochemistry with Clinical Correlations</i> , 2nd Edition: Ch. 8.5-8.6, 345-351 (1982)	

Examiner Signature	/Casey Hagopian/	Date Considered	01/28/2010
--------------------	------------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (01-09)
Approved for use through 02/28/2009. OMB 0551-0331
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/811,839
		Filing Date	March 30, 2004
		First Named Inventor	Theoharis C. THEOHARIDES
		Art Unit	1615
		Examiner Name	C. S. Hagopian
		Attorney Docket Number	2003133.00125US11
Sheet	5	of	6

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CI1	Simopoulos, A.P., Visioli F. (eds): Mediterranean Diets. World Rev. Nutr. Diet. Basel, Karger, Vol. 87: 56-77 (2000)	
	CJ1	Urade, Y. et al., "The Major Source of Endogenous Prostaglandin D2 Production is Likely Antigen-Presenting Cells," J. Immunol., 143(9): 2982-2989 (Nov. 1, 1989)	
	CK1	Lidor, C. et al., "Osteoporosis as the Sole Presentation of Bone Marrow Mastocytosis," J. Bone Min Res., Vol. 5(8): 871-876 (1990)	
	CL1	Kimata, M. et al., "Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells," Clin. and Exper. Allergy, Vol. 30, 501-508 (2000)	
	CM1	Letters to the Editor, J. Allergy Clin. Immunol., Vol. 119(2): 498-499 (Oct. 18, 2006)	
	CN1	Irani, A-M, et al., "Mast Cell Changes in Scleroderma," Arth. and Rheuma., Vol. 35(8): 933-939 (August 1992)	
	CO1	Dunn, R.T. et al., "Low-Dose Aspirin and Ibuprofen Reduce The Cutaneous Reactions Following Niacin Administration," Am. J. Ther., 2: 478-480 (1995)	
	CP1	Dvorak, A.M. et al., "Human Gut Mucosal Mast Cell: Ultrastructural Observations and Anatomic Variation In Mast Cell-Nerve Associations in vivo," Int. Archives of Allergy & Immunology, Vol. 98: 158-168 (1992)	
	CQ1	Cefali, E.A. et al., "Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulations," Int. J. Clin. Pharm. Ther., Vol. 45: 78-88 (2007)	
	CR1	Verbeek, R. et al., "Oral flavonoids delay recovery from experimental autoimmune encephalomyelitis in SJL mice," Biochem. Pharm., 70: 220-228 (2005)	
	CS1	Trichopoulos, A. et al., "Diet and Survival of Elderly Greeks: a link to the past1-4." Am. J. Clin. Nutri., Vol. 61(suppl.): 1346S-50S (1995)	
	CT1	Tsakalos, N. et al., "Induction of Mast Cell Secretion by Parathormone," Biochemical Pharmacology, Vol. 32(2): 355-360 (1983)	
	CV1	Theoharides, T. et al., "Bladder Mast Cell Activation in Interstitial Cystitis," Seminars of Urology, Vol. IX(2): 74-87 (May 1991)	
	CW1	Shoskes, D., et al., "Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial," Urology, 54(6): 960-963 (1999)	
	CX1	Seibold, J. et al., "Dermal Mast Cell Degranulation in Systemic Sclerosis," Arth. and Rheuma., Vol. 33(11): 1702-1709 (Nov. 1990)	
	CY1	Rockoff, S.D. and Armstrong, J.D. "Parathyroid Hormone as a Stimulus to Mast Cell Accumulation In Bone," Calc. Tiss. Res., 5: 49-55 (1970)	
	CZ1	Morrow, J.D., et al., "Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid," Prostaglandins, Vol. 38(2): 263-274 (1989)	

Examiner Signature	/Casey Hagopian/	Date Considered	01/28/2010
--------------------	------------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (01-09)
Approved for use through 02/28/2009. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	10/811,839	
			Filing Date	March 30, 2004	
			First Named Inventor	Theoharis C. THEOHARIDES	
			Art Unit	1615	
			Examiner Name	C. S. Hagopian	
			Attorney Docket Number	2003133.00125US11	
Sheet	6	of	6		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA2	Boushey, R. et al., "Adrenal Cortical Carcinoma," Curr. Treatment Op. Oncol., 2: 355-364 (2001)		
	CB2	Chines, A. et al., "Systemic Mastocytosis Presenting as Osteoporosis: A Clinical and Histomorphometric Study," J. Clin. Endocrinol. and Metab., Vol. 72(1): 140-144 (1991)		
	CC2	Singleton, V.L. and Rossi, J.A. "Colorimetry of Total Phenolics with Phosphomolybdic-Phosphotungstic Acid Reagents," Phenolics Determination, pp. 144-158		

Examiner Signature	/Casey Hagopian/	Date Considered	01/28/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.